Clinical Impact of Next‐Generation Sequencing–Detected Mutations on Thrombotic Events in Myeloproliferative Neoplasms
International Journal of Laboratory Hematology · 2026
DOI: 10.1111/ijlh.70123 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Laboratory Hematology, 2026. Verfasst von Ahmet Yigitbasi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Trakya University Faculty of Medicine, Department of Hematology, Edirne, Turkey. Hauptthemen laut MEDLINE: High-Throughput Nucleotide Sequencing, Thrombosis, Mutation, Myeloproliferative Disorders. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Introduction
Myeloproliferative neoplasms (MPNs), encompassing polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), are hematologic malignancies characterized by recurrent somatic mutations. Despite advances in next‐generation sequencing (NGS), the genetic basis of thrombotic risk and bone marrow (BM) fibrosis in MPNs remains unclear.
Methods
Patients diagnosed with classical MPN at Trakya University Faculty of Medicine were retrospectively analyzed (2018–2025). Mutation profiling was conducted on BM aspirates using a 78‐gene panel on the Illumina NextSeq platform, with clinically relevant variants (VAF ≥ 2%) interpreted via Qiagen Clinical Insight.
Results
Among 91 patients with MPN, the most frequent mutations were JAK2 (71.4%), TET2 (23.1%), DNMT3A (15.4%), ASXL1 (11%), and splicing factor mutations (SFMs; 12%). Arterial events occurred in 45.1% of patients and were associated with age ( p < 0.001), higher Charlson Comorbidity Index (CCI; p < 0.001), ASXL1 (p:0.019), and SFMs (p:0.009). VTE occurred in 38.5% and was associated with JAK2 status and allele burden (p:0.004 and p:0.012 respectively), TET2 ( p < 0.001), and SFMs (p:0.002); the JAK2/TET2 co‐mutant subgroup had the highest risk of VTE risk in multivariable analysis (OR: 2.9, 95% CI: 1.4–5.7; p:0.002). Advanced BM fibrosis was associated with SFMs (p:0.018). Increased mutational burden correlated with both venous and arterial thrombosis (p:0.021 and p:0.044, respectively). In survival analyses, SFMs (HR: 5.2; p:0.008), ASXL1 (HR: 3.8; p:0.030), and PMF diagnosis (HR: 3.8; p:0.045) were associated with inferior overall survival (OS).
Conclusion
Molecular profiling may provide clinically relevant thrombotic risk stratification in classical MPNs. JAK2/TET2 co‐mutation was linked to VTE, while ASXL1 and SFMs were associated with adverse phenotypes including vascular events, BM fibrosis, and inferior OS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Trakya University Faculty of Medicine, Department of Hematology, Edirne, Turkey.
- Trakya University Faculty of Medicine, Department of Pathology, Edirne, Turkey.
ORCID-Profile: Ahmet Yigitbasi, Elif Gulsum Umit, Fulya Oz Puyan, Hakki Onur Kirkizlar, Tugcan Alp Kirkizlar, Nuray Can, Guray Aygun, Ahmet Muzaffer Demir
Zitieren
APA
Yigitbasi, A., Umit, E. G., Puyan, F. O., Kirkizlar, H. O., Kirkizlar, T. A., Can, N., Aygun, G., & Demir, A. M. (2026). Clinical Impact of Next‐Generation Sequencing–Detected Mutations on Thrombotic Events in Myeloproliferative Neoplasms. International Journal of Laboratory Hematology. https://doi.org/10.1111/ijlh.70123
Vancouver
Yigitbasi A, Umit EG, Puyan FO, Kirkizlar HO, Kirkizlar TA, Can N, et al. Clinical Impact of Next‐Generation Sequencing–Detected Mutations on Thrombotic Events in Myeloproliferative Neoplasms. International Journal of Laboratory Hematology. 2026. doi:10.1111/ijlh.70123
BibTeX
@article{Yigitbasi2026,
author = {Yigitbasi, Ahmet and Umit, Elif Gulsum and Puyan, Fulya Oz and Kirkizlar, Hakki Onur and Kirkizlar, Tugcan Alp and Can, Nuray and Aygun, Guray and Demir, Ahmet Muzaffer},
title = {Clinical Impact of Next‐Generation Sequencing–Detected Mutations on Thrombotic Events in Myeloproliferative Neoplasms},
journal = {International Journal of Laboratory Hematology},
year = {2026},
doi = {10.1111/ijlh.70123}
}
EUVIMED